PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.51 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 16.67%. A quarter ago, it was expected that this company would post a loss of $0.52 per share when it actually produced a loss of $0.50, delivering a surprise of 3.85%. Over the last four quarters, the com ...

| --- | --- | --- | |--------------------------------------------------------------|-------|-------| | | | | | | | | | VISION: BECOME THE BPH TREATMENT OF CHOICE FOR ALL PROSTATES | | | | October 2024 | | | Safe Harbor Statement This presentation and accompanying oral presentation contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including the expected financial results of PROCEPT BioRobotics Corporation (the "Company"). Words such as "anticipat ...

PROCEPT BioRobotics® Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue and Adjusted EBITDA Guidance SAN JOSE, Calif., October 28, 2024 -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended September 30, 2024. Recent Highlights • Total revenue of $58.4 million for the third quarter of 2024, an incre ...

Financial Performance - Total revenue for Q3 2024 was $58.4 million, a 66% increase compared to Q3 2023 [2][3] - U.S. revenue for Q3 2024 was $52.2 million, a 62% increase compared to Q3 2023 [3] - U.S. handpiece and consumables revenue for Q3 2024 was $29.6 million, a 74% increase compared to Q3 2023 [2][3] - U.S. system and rental revenue for Q3 2024 was $19.6 million, a 46% increase compared to Q3 2023 [2][3] - International revenue for Q3 2024 was $6.2 million, a 122% increase compared to Q3 2023 [2][3] - Gross margin for Q3 2024 was 63.2%, compared to 53.8% in Q3 2023 [4] - Net loss for Q3 2024 was $21.0 million, compared to a loss of $24.6 million in Q3 2023 [5] - Adjusted EBITDA for Q3 2024 was a loss of $12.4 million, compared to a loss of $19.4 million in Q3 2023 [5] Full Year 2024 Guidance - The company projects full year 2024 revenue to be in the range of $222.5 million to $223.0 million, representing 63% to 64% growth over 2023 [5][6] - Full year 2024 gross margin is projected to be approximately 61%, up from previous guidance of 59% [6] - Full year 2024 Adjusted EBITDA loss is projected to be $60.0 million, improved from previous guidance of $67.5 million [6] Operational Highlights - The company sold 45 robotic systems in the U.S. in Q3 2024 at an average selling price of approximately $432,000 [2] - As of September 30, 2024, the install base of robotic systems in the U.S. was 445 systems [3] - The company successfully launched HYDROS in Q3 2024 after receiving FDA clearance in August 2024 [2] Industry and Product Focus - PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care in urology [8] - The company manufactures the AQUABEAM® and HYDROS™ Robotic Systems, with HYDROS being the only AI-powered robotic technology delivering Aquablation therapy [8] - Aquablation therapy is designed to treat lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH), impacting approximately 40 million men in the U.S. [8] - The company has over 150 peer-reviewed publications supporting the benefits of Aquablation therapy [8] Financial Position - Cash, cash equivalents, and restricted cash as of September 30, 2024, totaled $199.8 million [5] - Total current assets as of September 30, 2024, were $322.98 million, compared to $350.57 million as of December 31, 2023 [17] - Total liabilities as of September 30, 2024, were $132.92 million, compared to $123.97 million as of December 31, 2023 [18]

A downtrend has been apparent in PROCEPT BioRobotics Corporation (PRCT) lately with too much selling pressure. The stock has declined 15.7% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround. Here is How to Spot Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technic ...

PROCEPT BioRobotics Corporation (PRCT) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on October 28, 2024, might help the stock move higher if these key n ...

A Prospective, Randomized, Multicenter Study Assessing the Safety and Efficacy of Aquablation Therapy in Men with Grade Group 1 to 3 Localized Prostate Cancer Represents Potential Paradigm Shift in How Urologists Might Treat Localized Prostate Cancer SAN JOSE, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the U.S. Food a ...

SAN JOSE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 2024 Wells Fargo Healthcare Conference in Boston, Massachusetts. Management is scheduled to present on Wednesday, September 4 at 1:30 p.m. Eastern Time. A live webcast of each event, as well as an archived recording, will ...

1 IF D H HT T 100 - 100 1 i T 1 Pgiam/iStock via Getty Images Investment update Following my last publication on PROCEPT BioRobotics Corporation (NASDAQ:PRCT) around 12 months ago, the stock is +146% and now trades above $78/share. The most recent catalyst was the FDA's 510(k) approval of the company's HYDROS Robotic System ("Hydros"), extending PRCT's offerings in benign prostatic hypertrophy ("BPH") even further. Investors have bought PRCT on the news + the stock gapped above a key ~$70/share technical le ...

Company Update - PROCEPT BioRobotics announced FDA 510(k) clearance for its next-generation HYDROS Robotic System, marking a significant milestone in the adoption of Aquablation therapy [1] - The HYDROS Robotic System incorporates major technological innovations developed over years of research and is expected to drive the company's next growth phase [2] - The system is designed to enhance productivity, improve surgeon experience, and deliver precise, consistent treatment plans, with a full market release anticipated within the current quarter [4] Product Features - The HYDROS Robotic System features FirstAssist AI treatment planning, advanced image guidance, and robotic resection, aiming to provide superior clinical outcomes [5] - It integrates digital cystoscopy, next-generation ultrasound imaging, and dual high-definition touchscreens for improved anatomy visualization [6] - The system uses a heat-free waterjet to remove obstructive tissue while protecting vital structures, ensuring efficient and predictable execution across various prostate sizes [7] Industry Outlook - The global BPH treatment devices market was valued at $1.42 billion in 2022 and is projected to grow at a CAGR of 8.9% from 2023 to 2030 [8] - Growth is driven by technological advancements, increasing prevalence of urological illnesses, and rising patient awareness of minimally invasive treatment options [8][9] - Demand for innovative, minimally invasive technologies like Aquablation therapy is expected to rise due to fewer side effects and faster recovery times compared to traditional surgical methods [9] Stock Performance - PRCT's shares have gained 99% year-to-date, significantly outperforming the industry's 9.4% rise and the S&P 500's 17.8% increase [10]